Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07638852 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.

Study acronym: ABC-R
StatusRecruiting
PhasePhase 2
Started2026-02-02
View on ClinicalTrials.gov ↗

Amendment history

2026-09-03
Study Identification, Study Status, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility v3
Interventions modified
Eligibility criteria+59 characters
[...] esion has previously undergone radiotherapy, MRI is required. Confirm to confirm progression after radiotherapy;. Provide sufficient fresh tissue specimens or tumor samples (primary lesion and/or metastatic lesions) ≥10 smearsslides before treatment (preferably brain metastatic lesion specimens) for biomarker analysis. Use9. Patients receiving mannitol, hormonescorticosteroids, or anticonvulsants beforeprior to the first dose, butare eligible for enrollment if the drugdoses treatmentof dosethese mustconcomitant bemedications have been stable for at least one1 week without needingescalation, to [...]
Secondary endpoints16 entries, revised
Adverse Events (AE) NeurocognitiveHopkins functionVerbal assessmentLearning 1Test-Revised (HVLT-R) QualityFunctional Assessment of lifeCancer assessmentTherapy-Brain 1(FACT-Br) NeurocognitiveMini-Mental functionState assessmentExamination 2(MMSE) NeurocognitiveAnimal functionVerbal assessmentFluency 3Test NeurocognitiveTrail functionMaking assessmentTest 4(TMT-A/TMT-B) QualityEORTC ofQLQ-C30 EORTC life assessment 2 Quality of life assessment 3QLQ-BN20
Study title+15 characters
Study of Radiotherapy Combined With PlatinumCisplatin/Carboplatin, Adebrelimab and BevazumabBevacizumab in the Treatment of TNBC-BM.
2026-06-16
Study Status v2
Re-verified, no change to tracked fields
2026-06-13
Study Status v1
Start date2026-02-23→2026-02-02
2026-06-09
Original filing
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases.
Trial Details
NCT Number NCT07638852
Lead Sponsor Fudan University
Conditions TNBC, Triple Negative Breast Cancer, Brain Metastasases
Enrollment 58 participants
Start Date 2026-02-02
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-10